
Sanofi's Insulin Lispro Follow-On, Admelog, Wins FDA Approval
The cost of insulin has been a major policy issue in recent years. FDA Commissioner Scott Gottlieb, MD, said the approval of a new choice in insulin was a sign of his commitment to giving patients lower-cost options.
The FDA on Monday approved Admelog, the mealtime insulin from Sanofi that is a follow-on to Eli Lilly’s Humalog (insulin lispro), for the treatment of type 1 and type 2 diabetes. The action comes after FDA had given the product
Admelog is the first short-acting follow-on insulin to receive FDA approval; the agency previously approved Basaglar, the follow-on for Sanofi’s basal insulin, Lantus (insulin glargine, 100 units/mL). Following the arrival of Basaglar, Sanofi saw CVS Health replace Lantus with the follow-on on the
Since then, Basaglar sales have climbed: according to
FDA Commissioner Scott Gottlieb, MD, promised that the approval was the sign of things to come for patients. “One of my key policy efforts is increasing competition in the market for prescription drugs and helping facilitate the entry of lower-cost alternatives,” he said in
Insulin pricing has been a major policy issue in recent years. For example, the
As a result, the American Diabetes Association has called on Congress to investigate, and has
Admelog was approved quickly under FDA’s 505(b)(2) abbreviated pathway, which can be used to hold down drug development costs to keep products priced more reasonably for patients.
In
Besides Lantus, Sanofi has recently introduced the basal insulin Toujeo (insulin glargine, 300 units/mL).
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.